Home > Retinopathy of Prematurity > Quiz: ROP Pharmacologic Strategies Retinopathy of Prematurity Quiz: ROP Pharmacologic Strategies Ophthalmology 360 <section data-block="SingleChoice"><h3>What best describes the current standard management approach for ROP?</h3><ul><li>Early pharmacologic intervention targeting retinal vascularization</li><li>Observation and monitoring with intervention reserved for advanced disease</li><li>Routine use of anti-VEGF therapy in all cases</li><li>Prophylactic laser treatment in the proliferative phase</li></ul></section><section data-block="SingleChoice"><h3>Why is ROP described as an “orphan disease” in terms of pharmacologic therapy?</h3><ul><li>It occurs too rarely to justify drug development</li><li>Current treatments primarily address inflammation rather than vascular changes</li><li>There are no targeted pharmacologic therapies addressing its underlying pathophysiology</li><li>Existing drugs are unsafe in preterm infants</li></ul></section><section data-block="SingleChoice"><h3>Which adrenergic receptor subtype is primarily implicated in coupling hypoxia to excessive vascular growth during the proliferative phase of ROP?</h3><ul><li>β1-adrenoceptors</li><li>α1-adrenoceptors</li><li>β3-adrenoceptors</li><li>β2-adrenoceptors</li></ul></section><section data-block="SingleChoice"><h3>Propranolol is effective in infantile hemangioma primarily through which mechanism relevant to ROP?</h3><ul><li>Activation of β3-adrenoceptors to promote vascular regrowth</li><li>Non-selective β-adrenoceptor blockade preventing chaotic vessel proliferation</li><li>Selective inhibition of VEGF signaling</li><li>Direct stimulation of astrocyte migration</li></ul></section><section data-block="SingleChoice"><h3>What best describes the current standard management approach for ROP?</h3><ul><li>Early pharmacologic intervention targeting retinal vascularization</li><li>Observation and monitoring with intervention reserved for advanced disease</li><li>Routine use of anti-VEGF therapy in all cases</li><li>Prophylactic laser treatment in the proliferative phase</li></ul></section><section data-block="SingleChoice"><h3>Why is ROP described as an “orphan disease” in terms of pharmacologic therapy?</h3><ul><li>It occurs too rarely to justify drug development</li><li>Current treatments primarily address inflammation rather than vascular changes</li><li>There are no targeted pharmacologic therapies addressing its underlying pathophysiology</li><li>Existing drugs are unsafe in preterm infants</li></ul></section><section data-block="SingleChoice"><h3>Which adrenergic receptor subtype is primarily implicated in coupling hypoxia to excessive vascular growth during the proliferative phase of ROP?</h3><ul><li>β1-adrenoceptors</li><li>α1-adrenoceptors</li><li>β3-adrenoceptors</li><li>β2-adrenoceptors</li></ul></section><section data-block="SingleChoice"><h3>Propranolol is effective in infantile hemangioma primarily through which mechanism relevant to ROP?</h3><ul><li>Activation of β3-adrenoceptors to promote vascular regrowth</li><li>Non-selective β-adrenoceptor blockade preventing chaotic vessel proliferation</li><li>Selective inhibition of VEGF signaling</li><li>Direct stimulation of astrocyte migration</li></ul></section> Share Related Content Cornea and External Disease Quiz: The impact of blepharitis and conjunctivitis on quality of life Retina Care 360 Quiz: Mental health risks linked to age-related eye disease Dry Eye Quiz: Understanding meibomian gland dysfunction and its management Dry Eye Quiz: Emerging Therapies in DED Cornea and External Disease Quiz: Refractive Surgery in Patients With Diabetes Neurotrophic Keratitis Quiz: Topical Insulin for Persistent Corneal Epithelial Defects Share
